| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K27188169 | CTRPv2 | pan-cancer | AAC | -0.017 | 0.8 |
| mRNA | XMD15-27 | GDSC1000 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | BMS-345541 | GDSC1000 | pan-cancer | AAC | -0.0097 | 0.8 |
| mRNA | Lisitinib | GDSC1000 | pan-cancer | AAC | -0.01 | 0.8 |
| mRNA | isoevodiamine | CTRPv2 | pan-cancer | AAC | -0.01 | 0.8 |
| mRNA | BRD-K97651142 | CTRPv2 | pan-cancer | AAC | 0.011 | 0.8 |
| mRNA | PHA-665752 | CCLE | pan-cancer | AAC | -0.014 | 0.8 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0099 | 0.8 |
| mRNA | SCH-529074 | CTRPv2 | pan-cancer | AAC | 0.012 | 0.8 |
| mRNA | Nutlin-3a (-) | GDSC1000 | pan-cancer | AAC | 0.01 | 0.8 |